Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2010
08/31/2010US7786118 Temozolomide FDA Orange book listed patent; water soluble, and storage stable formulation; L-threonine as dissolution enhancer
08/31/2010US7786117 used for treating glaucoma, inflammatory bowel disease and alopecia
08/31/2010US7786116 2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
08/31/2010US7786115 Amide derivatives
08/31/2010US7786114 protein kinase inhibitors such as 5,6-Dimethoxy-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-pyrrolo[3,2-b]pyridine, used for the treatment of cancer
08/31/2010US7786113 Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents
08/31/2010US7786112 Small molecule antiproliferative agents
08/31/2010US7786111 Medicaments for the treatment of chronic obstructive pulmonary disease
08/31/2010US7786110 Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists
08/31/2010US7786108 Compounds and method for treating dyslipidemia
08/31/2010US7786107 Treating neurodegenerative diseases, psychological disorders, pain, glaucoma, dru eye, dry mouth, Sjogren's syndrome, asthma, bradycardia, wound healing, gastrointestinal disorders; amide- or urea-functional 1,2,3,4-tetrahydrospiro[benzo[b]azepine-5,4'-piperidine] rings; selective as to subtypes M1-M5
08/31/2010US7786106 such as 3-[(4-methoxybenzoyl)-amino]-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}phenyl beta -D-glucopyranoside, used as an activated blood coagulation factor X inhibitor; anticoagulants or preventive/therapeutic agents for diseases induced by thrombosis or embolism
08/31/2010US7786105 e.g. 1-[2-tert-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]-4-[3-(2-oxo-3,4-dihydroquinolin-1(2H)-yl)propyl]piperazin-4-ium chloride3,4-Dihydroquinolin-2(1H)-one; dopamine D3 receptor antagonists or agonists; antidepressant, schizophrenia, Parkinson's disease
08/31/2010US7786104 vanilloid receptor antagonists such as N-{6-[((R)-3-tert-Butoxycarbonylamino)pyrrolidin-1-yl]pyridin-3-yl}-5-fluoro-1-(3-fluorobenzyl)-1H-indole-2-carboxamide, used as analgesics, antidepressants, antidiabetic agents, and for the treatment of gastrointestinal disorders or neurodegenerative diseases
08/31/2010US7786103 Method for isolating an intestinal cholesterol binding protein
08/31/2010US7786102 Steroids as agonists for FXR
08/31/2010US7786101 A composition with drospirenone for pregnancy and cardiovascular diseases in women
08/31/2010US7786100 Composition and method of treating hearing loss
08/31/2010US7786099 such as A-ring aromatized Minocycline, having antibacterial activity; antibiotics
08/31/2010US7786098 (Z)-1-(3,4,5-trimethoxyphenyl)-2-(3'-amino-4'-trifluoroethoxyphenyl)-ethene, used to inhibit the polymerization of microtubules and for the treatment of tumor and neovascularization; anticarcinogenic agents
08/31/2010US7786097 Tricyclic compounds, compositions and methods
08/31/2010US7786096 Inhibition of antigen presentation with poorly catabolized polymers
08/31/2010US7786095 cyclodextrins; forming micelles or vesicles; used as hosts for the encapsulation, solubilization and/or stabilization of various compounds.
08/31/2010US7786094 Use of beta-glucans against biological warfare weapons and pathogens including anthrax
08/31/2010US7786093 saccharide containing 3-O-.alpha.-D-glucopyranosyl-D-glucose; nigerooligosaccharide; free from side effects; atrophy of thymus due to chronic stress is treated; nigerose, nigerosylglucose and nigerosylmaltose; food or beverage
08/31/2010US7786091 Usher 1B syndrome ocular disease; delivering subretinally to target cells; expression vehicle is HIV-1; CMV-MYO7A promoter or promoter active in photoreceptor or retinal pigment epithelium (RPE) cell; polynucleotide sequence encoding myosin VIIA; chromosomal integration sequence; gene therapy; blindness
08/31/2010US7786089 modulate an immune response through toll like receptors; 5'-TCGiTCGiTTCTC-Y-GiCTTGiCAAGiCT-5' (SEQ ID NO: 1), wherein X is a glycerol linker, Y is C3-1inker and Gl is 7-deazaguanosine
08/31/2010US7786088 Targeting vector to the urokinase plasminogen activator receptor
08/31/2010US7786048 Condensed heterocyclic pyrazole derivatives as kinase inhibitors
08/31/2010US7786042 Fluridone as an anti-inflammatory agent
08/31/2010US7786040 long lasting, plant safety; e.g. against powdery mildew
08/31/2010US7785891 Perfusion blood through tube coated with collagen; measure thrombosis and platelet aggregation; prevent cardiovascular disorders
08/31/2010US7785887 Which effect p53 binding/inactivation; enhances efficacy of such viruses for treating cancer; liposomes
08/31/2010US7785875 Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
08/31/2010US7785870 Cell-specific expression/replication vector
08/31/2010US7785817 Using caudal-1 gene (CDX-1) as diagnostic indicator of stomach or esophageal cancer; immunodiagnostics
08/31/2010US7785811 Using lutetium label probes to detect tumor secreted antigens and diagnose/prognose cell proliferative disorders
08/31/2010US7785808 Treatment of inflammation using α7 receptor-binding cholinergic agonists
08/31/2010US7785635 treating urinary tract infections, kidney stones in cats
08/31/2010US7785632 angiogenesis inhibitors; tetraiodothyroacetic acid conjugated to glycolide-lactide copolymer; binds cell surface receptor for thyroid hormone on integrin alpha at cell membrane level and does not activate signal transduction
08/31/2010US7785630 Mixture of active material in matrix of fatty alcohol or acid and solid hydrocarbon; microsphere
08/31/2010US7785627 Daily dosage form comprising: controlled release core of an antihyperglycemic drug and an excipient.seal coat applied to the controlled release core; and immediate release thiazolidinedione coating over the seal coat; metformin hydrochloride and pioglitazone hydrochloride FDA Orange book listed patent
08/31/2010US7785626 proton pump inhibitor and histamine H2 receptor antagonist; sustained release; for treatment of conditions associated with an excessive secretion of gastric acid; provides a suitable combination of a rapid onset and a long-lasting duration of the effect
08/31/2010US7785624 aqueous pharmaceutical formulation comprising at least one latrunculin wherein the formulation does not contain a substantial amount of dimethyl sulfoxide; for treating glaucoma, inhibiting wound healing after trabeculectomy, and inhibiting angiogenesis.
08/31/2010US7785622 comprises fentanyl as active ingredient, pressure-sensitive adhesive base, and tackifier resin; pressure-sensitive adhesive base comprising polyisobutylene and styrene/isoprene/styrene block copolymer; easily produced, has long-term continuity, and is excellent in adhesion and conformability to skin
08/31/2010US7785621 Oral compositions of fenretinide having increased bioavailability and methods of using the same
08/31/2010US7785620 Cholesterol lowering and blood lipids lowering composition
08/31/2010US7785619 Pharmanutrient composition(s) and system(s) for individualized, responsive dosing regimens
08/31/2010US7785618 Conjugates comprising a biodegradable polymer and uses therefor
08/31/2010US7785616 C-nitroso compounds and use thereof
08/31/2010US7785614 For use against vascular diesases or graft rejection.
08/31/2010US7785603 Polynucleotide comprising a first nucleic acid fragment which encodes at least 20 contiguous amino acids of an influenza virus polypeptide, wherein codons of nucleic acid fragment are optimized for expression in humans; enhancing immune response of vertebrate in need of protection against IV infection
08/31/2010US7785587 Mixture of corticosteroid and transforming growth factor inhibitor
08/31/2010US7785581 Composition and method for reducing feces toxins and treating digestive disorders
08/31/2010US7785578 Non-invasive ocular drug delivery
08/31/2010US7785573 Includes a UV-B active whose SPF rating is boosted by the presence in the composition of a phenylethyl, benzyl or substituted benzyl ester, which are arylcarboxylic esters of 2-phenylethyl alcohol, 1-phenylethyl alcohol, benzyl alcohol or substituted benzyl alcohol
08/31/2010US7784616 Dispenser for progestin used for acute maintenance treatment of DUB
08/31/2010CA2618271C Novel cyclohexenone compounds from antrodia camphorata and application thereof
08/31/2010CA2603274C Tetracyclic compounds, their preparation process and the pharmaceutical compounds containing them
08/31/2010CA2578130C Butylbenzene phthalein self-emulsifying drug delivery system, its preparation method and application
08/31/2010CA2574600C Pyridine derivatives
08/31/2010CA2569861C Pyrrolidine derivatives as ccr5 antagonists
08/31/2010CA2567981C Constrained himbacine analogs as thrombin receptor antagonists
08/31/2010CA2549558C Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
08/31/2010CA2549383C Nanoparticle compositions of water-soluble drugs for oral administration and preparation methods thereof
08/31/2010CA2540639C Salts and polymorphs of a pyrrole-substituted indolinone compound
08/31/2010CA2473152C Orally dispersible pharmaceutical piribedil composition
08/31/2010CA2462008C Systems, methods and apparatuses for manufacturing dosage forms
08/31/2010CA2447779C Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists
08/31/2010CA2397723C Brain, spinal and nerve injury treatment
08/31/2010CA2389545C Chemokine receptor binding heterocyclic compounds
08/31/2010CA2374226C Cinnamoylaminoalkyl-substituted benzenesulfonamide derivatives
08/31/2010CA2364493C Nitrate esters and their use for neurological conditions
08/31/2010CA2262010C Hsv strain lacking functional icp27 and icp34.5 genes
08/31/2010CA2259478C New salts of anionic complexes of ru(iii), as antimetastatic and antineoplastic agents
08/31/2010CA2227235C Novel galanthamine derivatives, preparation method therefor, use thereof as drugs, and pharmaceutical compositions containing such derivatives
08/26/2010WO2010096830A2 Method to treat psoriasis and other hyperproliferative skin disorders
08/26/2010WO2010096801A1 Estrogen receptor ligands and methods of use thereof
08/26/2010WO2010096798A1 Novel cephem compounds useful for the treatment of bacterial infections
08/26/2010WO2010096791A1 (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
08/26/2010WO2010096790A1 (+)-morphinananium n-oxides and processes for their production
08/26/2010WO2010096788A1 (+)-morphinanium quaternary salts and processes for their production
08/26/2010WO2010096778A1 Methods of and compositions for reducing cell death
08/26/2010WO2010096777A1 Inhibitors of hcv ns5a
08/26/2010WO2010096764A1 Iminosugars and methods of treating viral diseases
08/26/2010WO2010096751A1 Compositions and methods for treating a disease mediated by soluble oligomeric amyloid beta
08/26/2010WO2010096722A1 3-oxo-2, 3-dihydro- [1,2, 4] triazolo [4, 3-a]pyridines as soluble epoxide hydrolase (seh) inhibitors
08/26/2010WO2010096719A2 Anticancer and antimicrobial compounds from antarctic extremophilic microorganisms
08/26/2010WO2010096703A1 Amidobipiperidinecarboxylate m1 allosteric agonists, analogs and derivatives thereof, and methods of making and using same
08/26/2010WO2010096695A1 Antimicrobial compositions and uses thereof
08/26/2010WO2010096689A1 Compositions and methods for feeding poultry
08/26/2010WO2010096686A1 Methods of treating intestinal diseases and inflammatory conditions related to hiv-aids
08/26/2010WO2010096677A2 Dihydrolipoic acid derivatives comprising nitric oxide and therapeutic uses thereof
08/26/2010WO2010096572A2 Synthetic diblock copolypeptide hydrogels for use in the central nervous system
08/26/2010WO2010096551A2 Antimicrobial compositions
08/26/2010WO2010096539A1 Methods for treating lipomas and liposarcomas
08/26/2010WO2010096466A2 Methods and compositions for inhibiting cellular proliferation and surgical adhesion
08/26/2010WO2010096462A1 Linked diimidazole derivatives
08/26/2010WO2010096395A1 Amides as kinase inhibitors
08/26/2010WO2010096389A1 Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase